InsidersTradesSigma
Total declarations
Companies
▲ Purchases (8 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
8
Disclosed sells
0
T+90 hit rate
30%
T+90 mean return
-15.6%
Across 10 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the complete record of transactions filed by Meckler Jeffrey A, Chief Executive Officer. Officer active across 2 companies, notably Travere Therapeutics, Inc.. Cumulatively, 17 disclosures have been logged. Split: 8 buys · 0 sell. Total volume traded: €338k. History available since 14 May 2021. The latest transaction was disclosed on 15 May 2025 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations17 total
6,500 shares0Common StockSEC:0001415889-25-013500:0
42,553 shares@ US$1.1759.0% of flowCommon stockSEC:0001493152-24-047808:0
40,000 shares@ US$10.48100.0% of flowCommon StockSEC:0001415889-24-024117:0
84,932 shares@ US$1.82526.9% of flowCommon stockSEC:0001493152-24-030839:0
6,500 shares0Common StockSEC:0001415889-24-012848:0
4,500 shares0Common StockSEC:0001209191-23-030961:0
400 shares@ US$1.76370.1% of flowCommon stockSEC:0001493152-22-033241:0
Ideal exit: 15 Aug 2023 (T+270)
10,308 shares@ US$2.805.5% of flowCommon stockSEC:0001493152-22-025578:0
Ideal exit: 5 Jun 2023 (T+270)
1,060 shares@ US$2.440.5% of flowCommon stockSEC:0001493152-22-025319:0
Ideal exit: 3 Jun 2023 (T+270)
19,727 shares@ US$2.630.95% mcap15.9% of flowCommon stockSEC:0001493152-22-016027:0
Ideal exit: 3 Mar 2023 (T+270)
3,000 shares0Common StockSEC:0001209191-22-028697:0
11,187 shares@ US$5.8210.9% of flowCommon StockSEC:0001493152-21-029297
Ideal exit: 15 Aug 2022 (T+270)
11,187 shares@ US$5.821.13% mcap18.8% of flowCommon StockSEC:0001493152-21-029297:0
Ideal exit: 15 Aug 2022 (T+270)
12,000 shares@ US$7.001.40% mcap23.3% of flowCommon StockSEC:0001493152-21-022936:0
Ideal exit: 11 Jun 2022 (T+270)
12,000 shares@ US$7.0013.5% of flowCommon StockSEC:0001493152-21-022936
Ideal exit: 11 Jun 2022 (T+270)
3,000 shares0Common StockSEC:0001209191-21-033849
3,000 shares0Common StockSEC:0001209191-21-033849:0
17 of 17 declarations
About Meckler Jeffrey A
Jeffrey A. Meckler is President and CEO of Travere Therapeutics, Inc. and Indaptus Therapeutics, Inc. In these roles, he is responsible for the strategic and operational leadership of both companies. Jeffrey plays a key role in defining growth objectives and optimizing performance. His leadership is essential for ensuring the long-term success of Travere and Indaptus.
